Articles

Research articles on peptides, GLP-1s, SARMs, fitness, sleep, recovery, and longevity, written in plain English with primary citations.

Public articles

• The 10 peptides people run in 2026: where each stands (Peptides; 21 min read). Four of these ten have phase 3 trials behind them. The other six do not, and FDA has written a safety paragraph for every one. On July 23, 2026 an FDA advisory committee voted to recommend three of those six for compounding anyway, over the objection of FDA's own reviewers. Per compound: use, evidence, US status.
• GHK-Cu: what the copper peptide evidence actually shows (Peptides; 12 min read). GHK-Cu is a copper-carrying tripeptide sold two ways at once: as a mainstream cosmetic serum ingredient and as an injectable research vial. The evidence does not treat those two routes equally. This is an evidence map of what GHK-Cu has behind it, graded by use and route, plus how much copper a dose actually carries.
• Retatrutide + cagrilintide: what the stack rests on (Stacks; 11 min read). Reta and cag are sold pre-mixed, priced and dosed as though the pairing were a protocol. No registered trial has tested it. The closest measurement is CagriSema's phase 3, which ran an amylin, an incretin, and the combination as separate arms and put a number on what the amylin adds.
• Ozempic vs Wegovy: same drug, different label (GLP-1; 6 min read). People treat Ozempic and Wegovy like rival drugs, but they are the same molecule (semaglutide, from Novo Nordisk) injected once a week. The real differences are the approved use on the label, the top dose, and the brand, and that is what drives coverage and cost. Here is the plain side by side.
• BPC-157: a beginner's guide to the healing peptide (Recovery; 8 min read). BPC-157 is the most-searched healing peptide, and almost all the evidence behind it comes from animal studies, mostly rats. A plain-English starting point on what it is, what people use it for, what the research actually shows, the real risks, and where to read more before you decide anything.
• Retatrutide and muscle loss: what the trials show (GLP-1; 7 min read). Retatrutide takes off more weight than any obesity drug tested so far, which raises an obvious worry: how much of that is muscle. Here is what the body-composition scans actually found, why the lean-mass share is about the same as ordinary dieting, and the two levers with real trial evidence for keeping muscle while the weight comes off.
• TB-500: a beginner's guide to the recovery peptide (Recovery; 8 min read). TB-500 is the other half of the peptide healing stack, and almost everything behind it comes from animal studies of a different, larger molecule. A plain-English starting point on what it is, what people use it for, what the science actually shows, the real risks, and where to read more before you decide anything.
• Compounded semaglutide: a beginner's guide (GLP-1; 5 min read). Semaglutide is the drug inside Ozempic and Wegovy, and the compounded version is a pharmacy-made copy the FDA does not review for purity, strength, or dose. A plain-English starting point on what it is, what people use it for, what the science actually shows, the real risks of the vial-and-syringe format, and where to read more before you decide anything.
• Retatrutide: a beginner's guide to the triple agonist (GLP-1; 6 min read). Retatrutide is Eli Lilly's investigational triple-hormone shot for weight loss, and it is still in trials, not FDA-approved, and not sold as a finished drug. A plain-English starting point on what it is, what people use it for, what the trial numbers actually show, the real risks, and where to read more before you decide anything.
• Ipamorelin: a beginner's guide to the growth hormone peptide (Peptides; 5 min read). Ipamorelin is one of the most-searched growth-hormone peptides, usually stacked with CJC-1295. A plain-English starting point on what it is, what people use it for, what the small human evidence actually shows, the real risks, and where to read more before you decide anything.
• CJC-1295: a beginner's guide to the growth hormone peptide (Peptides; 6 min read). CJC-1295 is one of the most-searched growth-hormone peptides, usually stacked with ipamorelin, and it comes in two forms people constantly mix up. A plain-English starting point on what it is, what people use it for, what the small human evidence actually shows, the real risks, and where to read more before you decide anything.
• GHK-Cu: a beginner's guide to the copper peptide (Peptides; 6 min read). GHK-Cu is the copper peptide in skincare serums and the community 'glow stack,' and its evidence splits hard by route: strong-ish topical and cosmetic data, almost nothing for the injectable form. A plain-English starting point on what it is, what people use it for, what the research actually shows, the real copper risks, and where to read more before you decide anything.
• MK-677: a beginner's guide to the oral GH secretagogue (Peptides; 5 min read). MK-677 (ibutamoren) is the compound people keep mistaking for a peptide. It is an oral small molecule that pushes your body to release more of its own growth hormone. A plain-English starting point on what it is, what people use it for, what its unusually deep human trials actually showed, the real risks, and where to read more before you decide anything.
• Tesamorelin: a beginner's guide to the belly-fat peptide (Peptides; 6 min read). Tesamorelin is the one FDA-approved drug in this crowd, cleared for a single narrow use: cutting deep belly fat in adults with HIV-related fat changes. Off-label it gets used as a belly-fat finisher, but that use is unproven, it does not lower scale weight, the fat returns when you stop, and it is banned in tested sport. A plain-English starting point.
• PT-141: a beginner's guide to the desire peptide (Peptides; 6 min read). PT-141 is the peptide people reach for when desire drops or the usual erectile-dysfunction pills stop doing enough. It is FDA-approved as Vyleesi, but only for premenopausal women with low sexual desire; every other use is off-label and unstudied at that grade. A plain-English starting point on what it is, what the evidence really shows, and the nausea and blood-pressure catch.
• Why China makes your peptides, and how to vet quality (Research Gaps; 10 min read). The peptide world aims its quality anxiety at the certificate of analysis, but the bigger questions are where the powder is actually made and what a purity number leaves out. This piece covers why China and India dominate active-ingredient synthesis, why research-grade purity is not the same as pharmaceutical-grade sterility, and the red flags that survive the marketing.
• What is BAC water, and why do we use it? (Peptides; 9 min read). Bacteriostatic water, or BAC water, is the liquid most people mix their peptides and compounded GLP-1s with. It is plain sterile water with a small amount of benzyl alcohol added, and that one ingredient is the whole reason it works for a vial you plan to use for weeks. This is the beginner version: what BAC water actually is, how it differs from sterile water and saline, why the benzyl alcohol matters, and the two situations where it is the wrong choice.
• BPC-157: answers to the most common questions (Peptides; 12 min read). BPC-157 is one of the most talked-about peptides in the recovery world, and for good reason: it has a strong, consistent animal-healing signal, a plausible mechanism, a lot of positive user reports for tendon, joint, and gut recovery, and a human trial now recruiting. It is also early: the one completed randomized efficacy trial, in ulcerative colitis, did not separate from placebo, and nothing has been completed for a musculoskeletal use. Here are plain-English answers to the questions people actually ask (does it work, what for, capsule vs shot, is it legal, is it safe, the cancer worry), with the promise and the open questions both stated straight, and links to the deeper pieces when you want more.
• Ozempic and vision loss: NAION is real but very rare (GLP-1; 10 min read). The headlines said Ozempic can blind you, and that scared a lot of people off. Read the actual studies and what regulators concluded, and the picture is calmer than the headlines but not nothing: a rare eye stroke called NAION shows up about twice as often in semaglutide users. Because NAION is uncommon to start with, that doubling still lands at roughly one extra case per 10,000 people treated for a year. Here is the plain version, the numbers, and the warning sign that matters.
• Tirzepatide: answers to the most common questions (GLP-1; 9 min read). Tirzepatide is the drug behind Mounjaro and Zepbound, and if you are new to it the same questions come up every time. Is Mounjaro the same as Zepbound? How does the shot work, how is it dosed, how much weight do people lose, and does it come back if you stop? Plain-English answers below, with the numbers straight from the FDA labels and the trials, and links to the deeper pieces when you want more.
• Wegovy questions answered: the FAQs, with sources (GLP-1; 13 min read). The questions that actually come up about Wegovy, answered concisely and cited: how much weight people lose and why it plateaus, the side effects by percentage and how to blunt them, the rare red flags in context, dosing and missed shots, what stopping does, the cost, and whether compounded is still an option. Each answer links out to the longer piece when there is one, so this stays a quick reference.
• The Wegovy pill: oral semaglutide for weight loss (GLP-1; 7 min read). There is now a needle-free version of Wegovy, and it is not the same thing as the Rybelsus diabetes pill people keep confusing it with. Here is the plain version: what the oral semaglutide weight-loss pill is, what the OASIS-4 trial actually showed (and which number is the honest one), how it differs from Rybelsus, and the finicky dosing routine that is the price of skipping the needle.
• Retatrutide and fatty liver: what the trials show (GLP-1; 7 min read). Retatrutide keeps coming up in fatty-liver conversations because of one eye-catching number: in an early trial it cut liver fat by roughly 80 percent or more on the higher doses. That is real, and it is bigger than the drugs people usually compare it to. It is also an imaging result, not a biopsy, which matters more than the hype lets on. Here is the honest version: what the trial measured, why the glucagon arm makes retatrutide a liver-fat machine, and the gap between shrinking liver fat and actually treating liver disease.
• Retatrutide reconstitution and dosing: a practical guide (GLP-1; 12 min read). Retatrutide ships as a dry powder you mix yourself, so you have to set a concentration and then turn a milligram dose into syringe units. This is the plain version: what bacteriostatic water does, the concentration math with a worked example, the titration ladders the Phase 2 and Phase 3 trials used, why it is dosed once a week, and why reading syringe units as milligrams is the error that lands people in hospital.
• GLP-1 constipation: how long it lasts and what helps (GLP-1; 7 min read). Nausea gets the headlines, but constipation is the GLP-1 side effect that overstays its welcome. Here is the plain version: why a slowed gut backs you up, how common it is on semaglutide versus tirzepatide, the one number worth knowing (it tends to last far longer than the nausea), the boring fixes that genuinely work, and the rare warning signs that are a phone call rather than a fiber tweak.
• GLP-1s and gallstones: the gallbladder risk explained (GLP-1; 10 min read). Gallstones are one of the GLP-1 risks that rarely make the side-effect lists, but they are real, and two things drive them at once: the drug and the rapid weight loss it causes. The relative risk runs about a third higher, the absolute risk stays small, and the Wegovy and Zepbound labels report different numbers.
• Do you stop your GLP-1 before surgery or a colonoscopy? (GLP-1; 10 min read). GLP-1 drugs slow your stomach down, which is the whole point, until you are about to be sedated with food still sitting in it. Why a full stomach under anesthesia is the concern, how the advice moved from a blanket hold in 2023 to a risk-stratified plan in 2024 to a 2025 consensus that says stay on the drug and fast longer, where the societies still disagree, and why your care team has to make this call with you.
• Mazdutide: the GLP-1/glucagon dual agonist explained (GLP-1; 7 min read). Mazdutide is the next dual agonist to watch, and it pulls a different second lever than tirzepatide. Here is the plain version: what the GLP-1 plus glucagon combination actually does, what the phase 3 GLORY-1 trial showed, how it stacks up against the drugs you already know, and the two caveats that matter most, that it is approved in China but not in the US, and that every efficacy number so far comes from Chinese trials.
• Bimagrumab: the muscle-sparing partner for GLP-1s (GLP-1; 5 min read). One of the real costs of fast GLP-1 weight loss is muscle, and bimagrumab is the experimental answer aimed squarely at that problem. Here is the plain version: how an antibody that blocks a muscle brake builds muscle while burning fat, what the BELIEVE trial showed when it was added to semaglutide, the honest catch in that trial design, and why this is a promising idea that is still years from your pharmacy.
• How long can your GLP-1 stay out of the fridge? (GLP-1; 7 min read). Every GLP-1 question that starts with 'I left it out, is it ruined?' has a real answer, and it is printed on the label. The catch is that the answer is different for each drug, and different again for each device. This is the plain version: how long Ozempic, Wegovy, Mounjaro, Zepbound, and the semaglutide tablets can sit at room temperature, what freezing and heat mean for a pen, how to fly with your supply, and why a compounded vial follows its own rules.
• Does retatrutide cause low blood sugar (hypoglycemia)? (GLP-1; 6 min read). Retatrutide is the strongest of the new metabolic drugs, so it is fair to wonder whether it can crash your blood sugar. The short version is that its mechanism has a built-in brake against lows, and the trial in people without diabetes did not flag hypoglycemia as a notable problem. This is the plain explanation of why, plus the one situation where low blood sugar is a real risk worth planning for.
• SGLT2 inhibitors: how they work and the drug class (GLP-1; 6 min read). SGLT2 inhibitors are the 'gliflozin' pills, names like canagliflozin (Invokana) and dapagliflozin (Farxiga). They block a glucose transporter in your kidneys so you pee out some of your blood sugar. That sounds like a niche diabetes trick, and it started as one, but the same drugs turned out to protect the heart and the kidneys, so today they are prescribed for heart failure and chronic kidney disease too, in people with and without diabetes.
• Imcivree (setmelanotide): label, dosing, who it treats (Peptides; 6 min read). Imcivree (setmelanotide) is a once-daily under-the-skin injection for a short, specific list of rare obesity conditions, not a general weight-loss drug. It is an MC4 receptor agonist, acting on the brain receptor involved in regulating hunger, and in March 2026 its label grew to cover acquired hypothalamic obesity alongside Bardet-Biedl syndrome and three genetic deficiencies. This is the plain-language label guide: exactly who it is approved for, the dose by age and condition, what to do about a missed dose, and the warnings that actually come up, including the skin darkening that affects most patients.
• Loose skin after Ozempic: why it happens, what helps (GLP-1; 8 min read). Lose a lot of weight on a GLP-1 and the skin does not always shrink to match. People call it Ozempic body. How much you get tracks the size and speed of the loss and what your skin walked in with, and a couple of the levers are genuinely in your hands. Nobody has measured how much the drug itself adds on top of the weight loss.
• How to read a peptide COA: HPLC, mass spec, and fakes (Research Gaps; 12 min read). A certificate of analysis is the third-party test report that says what is in a vial and how pure it is, and it is worth something only if you can read one. This is the literacy layer. What HPLC purity actually measures and what it does not, what mass spectrometry confirms that purity cannot, why a certificate from the seller's own bench is not independent verification, how to read the report field by field, and the tells of a doctored, recycled, or unverifiable certificate. It is a tool you can point at any vendor, on any vial.
• Ozempic babies are real, and the reason is boring (GLP-1; 12 min read). Three things cause surprise pregnancies on GLP-1 drugs. On tirzepatide, slowed stomach emptying can blunt how the birth control pill is absorbed, and the label carries a warning and a specific instruction. On any of them, vomiting or diarrhea during titration can cost you a pill. And losing weight can restart ovulation in people who were not ovulating reliably. The plain version, by drug, with what each label tells you to do.
• Ozempic and hair loss: why it happens and when it stops (GLP-1; 8 min read). Some people notice more hair in the brush a few months into a GLP-1, and it is scary enough to make them think about quitting. In the weight-management trials it was reported by 3% to 6% of patients against about 1% on placebo, and the pattern is telogen effluvium, the temporary shedding that grows back. Rapid weight loss is the leading explanation, though 2026 comparator data leaves room for a drug effect on top of it.
• Microdosing GLP-1s: what it is and where it goes wrong (GLP-1; 8 min read). Microdosing means deliberately taking less than an approved GLP-1 dose, usually from compounded product bought outside the label. Whether the low dose does anything is untested, because the approved doses are the only ones studied rigorously. The documented harm is arithmetic: the FDA has logged overdoses of five to 20 times the intended dose on compounded semaglutide vials.
• Ozempic face: what it is and why it actually happens (GLP-1; 7 min read). Ozempic face is the gaunt, slightly older look some people get after fast weight loss on a GLP-1. Facial volume tracks the weight you drop: radiographic imaging in GLP-1 patients measured about 7 percent of midfacial volume gone for every 10 kg lost. What drives it, and what people do about it.
• What happens to your weight when you stop a GLP-1 (GLP-1; 8 min read). You hit your goal, or your prescription lapses, or you just want off the needle, and the obvious question follows: will the weight stay off? The honest answer from the trials that deliberately stopped the drug is that most people regain a large share of what they lost. Here is what the semaglutide and tirzepatide withdrawal studies found, why it happens, and what the data do and do not tell you about keeping it off.
• GLP-1 nausea and side effects: what actually helps (GLP-1; 10 min read). Nausea is the most common GLP-1 side effect, and the gut reactions rarely stop there. Why they happen, what genuinely helps the nausea, where sulfur burps, diarrhea, constipation, fatigue, and injection-site reactions fit, and what the head-to-head trial says about switching from semaglutide to tirzepatide.
• BPC-157 oral vs injectable: does the capsule work? (Peptides; 11 min read). BPC-157 is sold as both subcutaneous vials and oral capsules, and the marketing treats them as the same product. They are not. This separates what the rodent literature actually supports for each route, explains why a peptide that survives stomach acid still may not reach your bloodstream, and gives an honest read on choosing a route for a compound with no human pharmacokinetic data at all.
• Retatrutide weight loss timeline: what the trials show (GLP-1; 9 min read). You have heard the headline number on retatrutide: about a quarter of body weight in the Phase 2 trial. The question people ask next is when. Here is what the actual studies report, stage by stage, from the slow start while the dose climbs to the 80-week Phase 3 mark. These are trial averages, not a schedule you can bank on for yourself.
• Retatrutide side effects: the Phase 3 numbers compared (GLP-1; 12 min read). Five Phase 3 retatrutide trials have reported tolerability, and they do not agree. Which effects showed up, at what rate, when they hit, how many people stopped, and why the same 12 mg dose produced dysesthesia rates from 4.4 to 20.9 percent across five trial populations.
• The melanocortin system: MC4R, hunger, and its drugs (Peptides; 8 min read). One small receptor family, melanocortin 1 through 5, sits behind skin color, the stress-hormone axis, and appetite, and is the target of three very different approved peptide analogs. This is the whole family on one page: what each receptor does, which signal turns it on, and why a drug aimed at hunger can also tan your skin.
• How much weight can you actually lose on retatrutide (GLP-1; 9 min read). Retatrutide now has five positive Phase 3 readouts, and the weight-loss number moves a lot depending on which trial you read and who was in it. Here is what each one reported, at what dose, over what timespan, in which population, and counted which way, plus why a trial average is not a number you can bank on.
• Sulfur burps on GLP-1s: what to eat and what to cut (GLP-1; 5 min read). Rotten-egg burps are one of the most talked-about GLP-1 side effects, and they live almost entirely in food territory. Here is why a slowed-down stomach plus sulfur-heavy, fatty meals makes the smell, the foods worth easing off for a day or two, and the simple levers (smaller meals, real chewing, a walk after eating) that usually settle it.
• Oral peptide bioavailability: which peptides absorb (Peptides; 8 min read). Most peptides make terrible pills. The gut digests them and the intestinal lining blocks them, so oral bioavailability is typically below 1 percent. A short list of drugs gets around that, each with a different trick. Here is the route, the real absorption numbers from the labels and the PK literature, and what 'best oral peptide bioavailability' actually means.
• What food noise is, and why semaglutide quiets it (GLP-1; 6 min read). Food noise is the constant mental chatter about food that does not switch off: the snack you keep circling back to, the running tally of what you ate. A lot of people on semaglutide say it just goes quiet. Here is the plain version of what food noise is, why a weight and diabetes drug turns the volume down, and what that does and does not mean.
• Retatrutide and food noise: what the evidence says (GLP-1; 6 min read). People on retatrutide keep saying the same thing: the constant mental chatter about food just goes quiet. What its own trials measured, why the direct cravings measurement is still semaglutide's, and why the fact that retatrutide is still an investigational drug matters before you read too much into the quiet.
• How setmelanotide works: the MC4R hunger switch (Peptides; 7 min read). Setmelanotide (Imcivree) is the rare-obesity drug that works by replacing a missing brain signal. This is the plain-language mechanism: how the leptin-to-MC4R appetite pathway runs, where single genes and hypothalamic damage break it, what setmelanotide switches back on, and why the same action shows up as darker skin.
• CJC-1295 + ipamorelin vs HGH: what the data shows (Peptides; 10 min read). Growth-hormone peptides like CJC-1295 and ipamorelin get marketed as a softer, legal alternative to injectable HGH. They are not the same thing. One is an FDA-approved hormone with a decades-long trial record; the other two are unapproved research peptides with thin human data. This walks the mechanism, the actual evidence, what the bloodwork measures, and the legal and anti-doping reality.
• Beyond Ozempic: how GLP-1s lit the peptide boom (GLP-1; 12 min read). Semaglutide and tirzepatide turned a pharmacology word, 'peptide', into a consumer category. The GLP-1 drugs earned the attention with hard trial numbers. The compounds being marketed in their slipstream, growth-hormone secretagogues like CJC-1295 plus ipamorelin and a long tail of gray-market metabolic peptides, mostly have not. This separates the two and explains the compounding fight underneath.
• Lead in Protein Powder: 2025 Consumer Reports Test (Fitness; 9 min read). Consumer Reports retested 23 popular protein powders and shakes in October 2025 and found more than two thirds carried more lead per serving than CR's 0.5 microgram daily reference. Plant-based ran nine times the dairy average. The Clean Label Project's separate January 2025 whitepaper added the counterintuitive organic-worse and chocolate-worse findings, but the two studies do not agree on flavor effects. California SB 1033 would force lot-level disclosure starting January 2028.
• Peptide dosing: mg, mcg, units, and the math that works (Peptides; 12 min read). Milligrams, micrograms, and "units" describe three different things, and new users keep treating them as interchangeable. A milligram is mass. A microgram is one thousandth of that mass. A unit on an insulin syringe is a volume convention borrowed from U-100 insulin. The arithmetic that ties them together depends on a concentration the user picked at reconstitution, and the FDA has a documented harm record for getting it wrong.
• Vetting peptide providers: who to trust, who to skip (Research Gaps; 22 min read). Peptide marketing has outrun peptide regulation. This piece maps the supply routes a US buyer actually has: which clinicians can prescribe, what 503A pharmacies and 503B outsourcing facilities are each allowed to do, what FDA is doing to both routes now, and how to check a supplier when no prescriber is in the chain.
• Combination peptide stacks: which have real evidence (Peptides; 16 min read). Integrative clinics now bundle peptides with hormone replacement, IV nutrient infusions, resistance training, and lifestyle coaching. The evidence base across those layers is wildly uneven, and the article breaks the stack into three honest buckets so a reader can tell controlled-trial support from clinic-program convention.
• Retatrutide vs Tirzepatide: trials and field reports (GLP-1; 23 min read). Retatrutide is Eli Lilly's investigational triple agonist (GIP, GLP-1, glucagon). Tirzepatide (Mounjaro, Zepbound) is the dual GIP/GLP-1 agonist already on label. Five retatrutide Phase 3 trials have reported, across five trial populations; the head-to-head is still running. This walks the trial numbers side by side and adds what users report, flagged as the weaker source.
• Peptides in 2026: the biohacker's no-BS field guide (Peptides; 20 min read). A blunt roundup of where the 2026 peptide market actually sits across healing, fat loss, and longevity. Names the compounds that carry real human trial evidence (a small group of GLP-1s), the ones with a real preclinical signal and almost no human trials (BPC-157, TB-500, GHK-Cu), and the ones that are informed bets on mechanism (rapamycin, NMN, NR, MOTS-c, senolytics). Then walks the four risk vectors that decide whether any peptide protocol survives contact with a real vial.
• KLOW stack: KPV, LL-37 and oxytocin evidence review (Stacks; 14 min read). KLOW is a community shorthand for a four-part blend of KPV, LL-37, Oxytocin, and the Wolverine pair (BPC-157 plus TB-500). It is not an FDA-approved protocol, has no controlled human trial as a stack, and most of its individual components also lack large human efficacy data. This piece works through what each constituent does, where the evidence sits, and where the stack story outruns the data.
• GLOW stack: GHK-Cu, BPC-157 and TB-500 evidence review (Stacks; 11 min read). GLOW is community shorthand for a three-part blend of GHK-Cu, BPC-157, and TB-500 marketed for skin quality, collagen, and recovery. It is not an FDA-approved protocol and has no controlled human trial as a stack. This piece walks through each component, where the evidence is real, and where the marketing leans on extrapolation from topical or animal data.
• The wild west of peptides: hype, safety and the gaps (Research Gaps; 12 min read). Peptide demand outran the trial base because social-media marketing got there first. The real-world risk sits in sourcing, identity, purity, endotoxin, and dose drift on vials that were never built to be drugs. This is the safety-and-evidence companion to the in-demand-peptides market watch.
• Will your body stop making peptides if you inject them? (Research Gaps; 12 min read). Whether injecting a peptide trains the body to stop making its own depends entirely on which peptide is in the vial. BPC-157, TB-500, and GHK-Cu have no published feedback loop for an exogenous version to suppress. With CJC-1295 and tesamorelin the pituitary kept responding across the studied dosing windows and the effect reverted after the drug stopped. GLP-1 drugs are the one group where the body's own output has been measured in humans, and the results split by drug. Access is the more durable worry.
• Most in-demand peptides of 2026: what's hyped, what works (Peptides; 15 min read). Six non-GLP-1 peptides carry the visible 2026 attention: BPC-157, CJC-1295 plus ipamorelin, semax, selank, TB-500, and melanotan II. What the human evidence actually shows, where marketing outruns the trials, what each one is banned for in tested sport, and which one has documented harm.
• GLP-1s beyond weight: HFpEF, PAD, and PCOS explained (GLP-1; 12 min read). GLP-1 receptor agonists have moved past obesity and type 2 diabetes into a set of candidate indications. STEP-HFpEF, STEP-HFpEF DM, and the tirzepatide SUMMIT trial built the heart failure with preserved ejection fraction case. STRIDE produced the phase 3b walking-capacity readout in peripheral artery disease with type 2 diabetes. PCOS still rests on meta-analysis of small trials. This piece walks each indication, the trial behind the signal, and where the regulators actually landed.
• Wolverine Stack BPC-157 and TB-500: what the evidence says (Peptides; 12 min read). The Wolverine Stack is community shorthand for pairing BPC-157 with TB-500, usually for injury recovery. The evidence is mostly preclinical for BPC-157 and mostly extrapolated from full-length thymosin beta-4 for TB-500, so the stack is not an FDA-approved protocol or a validated clinical treatment.
• Orforglipron (Foundayo): the approved oral GLP-1 pill (GLP-1; 16 min read). Orforglipron is now an approved US drug sold as Foundayo. This piece reads the label against the four Phase 3 trials: what it is approved for, the 0.8 to 17.2 mg dose ladder, how the trial doses map onto it, the boxed warning, how 11.2 percent in ATTAIN-1 sits next to the injectables, and what switching from an injection to the pill held onto.
• Wegovy HD and CagriSema, the next bar for injectable GLP-1s (GLP-1; 11 min read). The FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026, after STEP UP showed about 20.7 percent mean weight reduction at 72 weeks in participants who took the drug as randomized. CagriSema (cagrilintide plus semaglutide) reported 22.7 percent on the trial-product estimand in REDEFINE-1 and 13.7 percent in REDEFINE-2 (type 2 diabetes). Wegovy HD is approved; CagriSema is investigational, filed with the FDA in December 2025.
• PT-141 and Vyleesi: what bremelanotide is approved for (Peptides; 10 min read). Bremelanotide (Vyleesi) is an FDA-approved subcutaneous melanocortin receptor agonist for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The RECONNECT program anchored a narrow label. This piece walks the pivotal data, the mechanism, the safety profile, and what sits outside the approval.
• MOTS-c: mitochondrial peptide, mostly rodent evidence (Peptides; 7 min read). MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. The rodent metabolic work (Lee 2015, Cell Metabolism) reproduces, but human evidence is still observational. No trial of administered MOTS-c has read out; the first Phase 2a study is only now recruiting.
• Setmelanotide (Imcivree): what the FDA label covers (Peptides; 11 min read). Setmelanotide (Imcivree) is an MC4R agonist approved by the FDA for three narrow populations: POMC, PCSK1, and LEPR deficiency, Bardet-Biedl syndrome, and, since March 2026, acquired hypothalamic obesity. This piece walks the mechanism, the indication-by-indication label, the trial numbers, and the boundary between approved use and the broader MC4R framing.
• Kisspeptin-10 and the HPG axis: the human evidence (Peptides; 8 min read). Kisspeptin is the upstream gatekeeper of the hypothalamic-pituitary-gonadal axis. The published human trial literature is real and growing, but most of it uses kisspeptin-54, not the research-vial kisspeptin-10 that the community calls KP-10. This piece walks the KISS1R biology, the trial program in functional hypothalamic amenorrhea and IVF, and the gap between trial peptide and research-vial peptide.
• AOD-9604 fat loss: what the human trials actually showed (Peptides; 6 min read). AOD-9604 is a synthetic fragment of human growth hormone that vendors sell as a fat-loss peptide. It reduces fat in rodents, and six placebo-controlled human trials were run for obesity. The larger 24-week trial did not beat placebo on weight, the developer dropped the obesity program, and there is still no approved AOD-9604 drug.
• Retatrutide: triple agonist, 28.7% loss in TRIUMPH-4 (GLP-1; 10 min read). Retatrutide is Eli Lilly's investigational once-weekly injectable that activates three incretin and metabolic receptors at once: GIP, GLP-1, and glucagon. The Phase 2 trial reported mean weight reductions of about 24 percent at 12 mg over 48 weeks, and the first Phase 3 readout (TRIUMPH-4, December 2025) reported up to 28.7 percent at 68 weeks alongside improvements in knee pain and several cardiometabolic markers. This piece walks the pharmacology, the trial data, what the comparison to earlier GLP-1 drugs actually shows, and what the rest of the TRIUMPH program is adding.
• FDA peptide compounding 2026: BPC-157, TB-500, and PCAC (Peptides; 12 min read). BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon did not get FDA-approved in April 2026. They came off FDA's Category 2 safety list after their nominations were withdrawn, and at the July 23-24 PCAC meeting the advisory committee voted by narrow margins, against FDA's own staff, to recommend six of the seven for the 503A Bulks List. That vote does not bind FDA and none of them is compoundable today. The evidence question is messier than either the hype or the panic admits.
• What standard blood panels catch, and what they miss (Research Gaps; 11 min read). A widely shared sign puts it bluntly: "standard blood panels are designed to keep you out of the ER, not tell you why you feel like garbage." The framing is overstated, but the underlying complaint is real. Standard panels (CBC, BMP/CMP, lipid panel) were built to screen for the acute or organ-level problems a clinician cannot afford to miss. They were not built to explain why a person inside reference range still feels exhausted or off. This piece covers what standard panels actually screen for, why reference ranges are statistical bands rather than wellness verdicts, the five most common gaps where they miss symptom-relevant pathology (subclinical hypothyroidism, low ferritin without anemia, vitamin D and B12 insufficiency, early insulin resistance, and low-normal sex hormones), and the targeted second-tier labs that close those gaps.
• GLP-1 drugs and alcohol cravings: the trial evidence (GLP-1; 13 min read). GLP-1 receptor agonists like semaglutide, tirzepatide, and exenatide show a consistent but still investigational signal that they reduce alcohol craving and consumption. Two semaglutide randomized trials now back it: a 2025 phase 2 study in JAMA Psychiatry and a larger 26-week trial in The Lancet in 2026 that hit its heavy-drinking-days endpoint in patients with comorbid obesity. A 2022 exenatide trial missed its overall primary endpoint but reduced brain reward-cue reactivity and helped a higher-BMI subgroup. Real-world cohorts and a 2025 meta-analysis line up on direction. No GLP-1 drug is FDA-approved for alcohol use disorder. This piece walks the trials, the mechanism, and the gaps.
• GLP-1 cardiovascular outcomes: SELECT, FLOW, and more (GLP-1; 7 min read). GLP-1 receptor agonists started as glycemic drugs and matured into cardio-renal-metabolic drugs. SELECT brought a 20 percent reduction in major cardiovascular events to non-diabetic patients with obesity. STEP-HFpEF showed symptomatic and weight benefit in obesity-driven HFpEF. FLOW reported a 24 percent reduction in major kidney outcomes in type 2 diabetes plus chronic kidney disease. Below, the trial designs, the effect sizes, what each trial left open, and the FDA label changes that followed.
• Tirzepatide for sleep apnea: the SURMOUNT-OSA result (GLP-1; 7 min read). Obstructive sleep apnea is the most common sleep-disordered breathing condition, and obesity is its leading modifiable risk factor. The two SURMOUNT-OSA trials tested whether tirzepatide could cut the apnea-hypopnea index (AHI) in adults with moderate-to-severe OSA and obesity, in patients both off and on positive airway pressure. It did, by 25 to 29 events per hour over 52 weeks, and the FDA approved Zepbound for the OSA indication in December 2024. What the trials did not settle is whether that AHI drop means fewer heart attacks, deaths, or crashes.
• Creatine monohydrate: what 30 years of evidence shows (Fitness; 7 min read). Creatine monohydrate is one of the most studied sports-nutrition supplements, with an old and deep evidence base. Decades of randomized trials and meta-analyses land on a small-to-moderate strength and lean-mass benefit at 3 to 5 grams per day, with a clean safety record in healthy adults. The cognitive signals are real but small, and concentrated in sleep-deprived and older adults.
• Omega-3 and cardiovascular outcomes: EPA vs fish oil (Longevity; 7 min read). Omega-3 supplementation has more conflicting trial data than almost any other widely sold supplement. REDUCE-IT showed a 25 percent relative risk reduction in major cardiovascular events with high-dose icosapent ethyl in statin-treated patients with elevated triglycerides. STRENGTH was neutral with a different EPA plus DHA carboxylic acid formulation. VITAL was neutral on primary cardiovascular outcomes with low-dose marine n-3 in a primary-prevention population. This piece walks the trial designs, the formulation differences, the placebo controversy, and what current clinical guidance actually says.
• Vitamin D supplements and the VITAL trial verdict (Longevity; 7 min read). VITAL is the largest trial of vitamin D in generally healthy adults: 25,871 people over five years, null on its primary cancer and cardiovascular endpoints, and null on fractures. The value here is separating two questions people keep merging: routine supplementation in already-replete adults, and treating documented deficiency.
• Zone 2 training: lactate threshold and mitochondria (Fitness; 7 min read). Zone 2 has become a popular endurance prescription, sold as the workout that builds mitochondrial density and improves fat oxidation. The physiology behind it (lactate kinetics, mitochondrial biogenesis, and the low-intensity-heavy training distribution documented in elite athletes) is well grounded. The popular dosing prescriptions run looser than the trial evidence supports, and the specific dose-response is still unsettled.
• CGMs in non-diabetic adults: signal versus noise (Research Gaps; 7 min read). The FDA cleared the first over-the-counter continuous glucose monitors for adults who do not use insulin in 2024: Dexcom Stelo in March, Abbott Lingo and Libre Rio in June. The marketing has run ahead of the evidence. These sensors reliably show post-meal glucose swings, but in non-diabetic adults the trial data on whether acting on that improves weight, HbA1c, or any hard outcome is thin.
• Time-restricted eating: TREAT, TIME, and calorie deficit (Fitness; 7 min read). Time-restricted eating limits the daily eating window without setting a calorie target, and it has been one of the most popular diet patterns of the last decade. The trial record is more deflating than the hype. TREAT (Lowe 2020) and the TIME trial (Liu 2022, NEJM) both found that time-restricted eating did not beat non-restricted-window controls or daily calorie restriction at matched intake. The weight loss it produces tracks total calories eaten, and adherence is the practical lever.
• Heart rate variability: the evidence and the hype (Recovery; 6 min read). Heart rate variability (HRV) has become a staple of consumer wearables, sold as a quantitative readout of recovery, stress, and fitness. The underlying autonomic-cardiac physiology is real, small randomized trials have tested HRV-guided training in endurance athletes, and prognostic data tie low resting HRV to higher mortality at the population level. The consumer marketing runs well past what those studies support, and the gap is widest at the wrist, where optical sensors trade ECG-grade accuracy for convenience.
• Magnesium supplements: the RCT evidence, claim by claim (Recovery; 6 min read). Magnesium is an essential mineral, a cofactor in more than 300 enzyme systems, and a popular supplement marketed for sleep, cramps, anxiety, and cardiometabolic health. Intake gaps are common but frank deficiency is not. The trial record is mixed and claim-specific. Some uses (severe deficiency, eclampsia, certain arrhythmia contexts) are well-established; others (sleep onset, leg cramps, generalized anxiety) rest on small or low-quality trials. This piece walks the dietary intake gap, the form-specific absorption differences, the published RCT evidence claim by claim, and the safety profile.
• GLP-1 reconstitution and titration: the real dose risk (GLP-1; 11 min read). Self-titrating a compounded GLP-1 is sold as simple arithmetic, and the multiplication is the easy part. What breaks is the conversion chain from milligrams to draw volume to syringe markings, and climbing the dose faster than the labeled ladder. This covers both, with the error modes a dose calculator alone misses.
• Oral peptides and the gut barrier: what gets through (Peptides; 7 min read). Most peptides do not survive the stomach. The few that do still have to cross the mucus layer, the brush border, and the tight-junction lattice between gut cells. That is why oral semaglutide needs an absorption enhancer to reach even 1 percent, and why most peptides sold as capsules have no human oral pharmacology at all.
• Body recomposition vs weight loss: what DXA reveals (Fitness; 6 min read). The scale reports total mass. DXA separates fat mass, lean mass, and bone mineral content. Trials report both, and they often disagree about whether an intervention is working. Here is what each measurement actually reflects, where the disagreement comes from, and what the published recomposition research supports.
• Peptide bioavailability: why route matters more than dose (Peptides; 9 min read). Bioavailability is the percentage of an administered dose that reaches systemic circulation in active form. For peptides, the answer depends mostly on the route. Subcutaneous, intramuscular, intranasal, oral, and buccal each deliver very different fractions of the same molecule. Here is the route-by-route picture from approved labels and published pharmacokinetic studies.
• How to read medical evidence without a degree (Research Gaps; 9 min read). Peptide and GLP-1 discussions lean on published studies, and most readers never check how those studies were built. The tools to check are learnable: the evidence hierarchy, what a p-value really reports, why effect size beats statistical significance, and the questions that tell a solid study from a thin one.
• Why GLP-1 weight loss plateaus: what the trials show (GLP-1; 5 min read). GLP-1 agonists rarely produce a smooth weight curve. The plateau most users hit is built into the biology. This piece covers the receptor and energy-balance mechanisms behind it, the named trial nadirs, the adaptive-thermogenesis data, and the dose and multi-receptor strategies that delay the bend.
• BPC-157: what the human evidence actually shows (Peptides; 17 min read). BPC-157 is widely used and thinly studied in people. This maps the rodent literature, the five human studies the FDA has now catalogued, the July 2026 compounding decision, the WADA ban, and the identity problem with what is actually in the vials, then says what would move the evidence.
• Peptide storage and stability: what actually degrades it (Peptides; 9 min read). Lyophilized peptide keeps for months to years. The moment you add water the clock speeds up, and temperature, light, pH, and freeze-thaw all set the pace. What the degradation chemistry actually is, the FDA-labeled in-use windows worth borrowing for a reconstituted vial, the bacteriostatic-water question, and how to read a certificate of analysis.
• SARMs regulatory reality: not approved, still banned (SARMs; 8 min read). What FDA enforcement, WADA prohibition, and the failed federal scheduling attempts actually mean for SARMs in 2026, why the 'research only' label that ships on most products is regulatory cosplay rather than legal cover, and what the published clinical-trial record actually says about MK-2866, LGD-4033, and RAD-140.
• Sleep architecture and recovery: slow-wave sleep and GH (Sleep; 7 min read). Most recovery biology in sleep happens during specific stages, concentrated in the first half of the night. This covers the sleep stages, the slow-wave-sleep and growth-hormone coupling (Van Cauter; Diekelmann and Born), how alcohol, caffeine, and exercise shift sleep architecture, and what supplements and peptides actually do.
• Injection site rotation, lipohypertrophy, and absorption (Peptides; 6 min read). Repeated injections into the same spot remodel the fat under your skin into lipohypertrophy, and a dose from that tissue absorbs slower and less predictably. This covers the prevalence data, the FITTER injection-technique consensus, the Famulla absorption study, needle length, the GLP-1 site-specific PK question, and basic aseptic technique.
• Protein, leucine, and hypertrophy: the real thresholds (Fitness; 5 min read). The popular framing of protein and muscle-protein synthesis sits on a real research base, but the practical recommendations are often stronger than the underlying evidence supports. This piece covers the named tracer studies (Moore, Witard, Macnaughton), the leucine threshold per meal, anabolic resistance with age, the bolus-vs-frequency randomized data, total-daily-protein meta-analyses, and the GLP-1-deficit application.
• VO2max as a longevity marker: the cohort evidence (Longevity; 7 min read). VO2max tracks all-cause mortality across large cohorts, one of the most replicated associations in the field. No trial has shown that raising VO2max lowers death rates. Covers the named cohorts (Mandsager 2018, Imboden 2018, Kokkinos 2022), the dose-response, VO2max by age and sex, and what training moves.
• Mitochondrial density and training: zone 2 vs HIIT (Fitness; 6 min read). Podcasts collapse mitochondrial training to one heart-rate zone. The biopsy and stable-isotope literature is blunter: moderate continuous work and intervals both build mitochondria, sprint intervals reach similar gains on far less total work, and zone 2 mostly buys sustainable volume. No supplement replaces the training.
• NAD precursors: what NMN and NR trials actually show (Longevity; 8 min read). NMN and NR reliably raise blood NAD+ markers at supplement doses, but every published human trial stops at surrogate endpoints, not mortality or disease outcomes. The rules also shifted: the FDA reversed its 2022 exclusion of NMN in September 2025, so NMN is a lawful dietary ingredient again, while NR (Niagen) keeps the longer GRAS and NDI record.
• GLP-1 and muscle loss: how to protect lean mass (GLP-1; 8 min read). Rapid weight loss always sheds some lean mass, and a GLP-1 is no exception: about a quarter to a third of what you lose is lean tissue on DXA, the same split as fast dieting or surgery. How much muscle you keep tracks with resistance training, protein, and how fast you lose, all of which you control regardless of the drug.
• Women and peptide research gaps: the missing data (Research Gaps; 5 min read). Most early GLP-1 and peptide pharmacology was worked out in male-skewed cohorts, so dose interpretation in women rests on smaller samples than the labeled doses suggest. Modern GLP-1 obesity trials fixed that. Older research peptides and SARMs did not. Here is where the sex-data gap has closed and where it has not.
• Cold exposure and recovery: soreness vs hypertrophy (Recovery; 6 min read). Cold-water immersion has decades of sports-medicine data behind it. At 10-15 C for 10-15 minutes it cuts next-day muscle soreness, but used right after lifting it also blunts muscle and strength gains. This covers what the controlled trials measured, the hypertrophy trade-off included, and why cold showers are a weaker stimulus.
• Sauna and cardiovascular outcomes: what the evidence says (Recovery; 7 min read). The Finnish KIHD cohort produced the headline sauna numbers, and they are large. The randomized trials that followed cannot answer the causal question and mostly come up flat on vascular endpoints. This piece covers the named KIHD findings (Laukkanen 2015 mortality, 2017 dementia, Zaccardi 2017 hypertension), the acute hemodynamics, the heat-shock biology, the honest comparison to exercise, and the real contraindications.
• Compounded GLP-1 vs labeled: what the FDA says (GLP-1; 19 min read). Compounded semaglutide and tirzepatide are not generic Wegovy or Zepbound. They sit in a regulatory gap the FDA has flagged repeatedly. This covers the 503A vs 503B framework, the shortage history that opened the lane and the 2024 to 2026 closing of it, the essentially-a-copy test that governs the vials still on sale, the salt-form problem, the documented dosing-error overdoses, the telehealth and international channels, and what the trial data does and does not carry over.
• Tesamorelin and visceral fat: what the trials show (Peptides; 8 min read). Tesamorelin has a narrow FDA label and real phase 3 evidence behind it: about a 15 percent visceral-fat reduction by CT, but only in HIV-associated lipodystrophy. Off-label the evidence thins fast, the IGF-1 and glucose monitoring gets skipped, and the fat returns within months of stopping.
• Wearable sleep tracking accuracy vs polysomnography (Sleep; 6 min read). Your wrist wearable draws a sleep-stage chart that looks like polysomnography. The validation data is blunter: total sleep time is close, wake detection is poor, and stage breakdown lands around 50 to 70 percent. This covers what the devices actually sense, the head-to-head numbers from 2021 through 2025, why sleep scores do not compare across brands, and when to get a real sleep study.
• Senolytics: dasatinib, quercetin, and the human data (Longevity; 7 min read). Senolytics look strong in aged mice. The human evidence is thinner: a handful of small open-label pilots on surrogate endpoints. This piece covers the dasatinib plus quercetin (D+Q) pilots (Justice in IPF, Hickson in diabetic kidney disease), the failed UBX0101 osteoarthritis trial, fisetin, the dasatinib safety profile, and why senescent-cell burden is hard to measure.
• Rapamycin off-label: the longevity evidence (Longevity; 9 min read). Rapamycin (sirolimus) is an approved immunosuppressant that a longevity crowd takes off-label. The mouse-lifespan data is strong and well-replicated; the human data is small, short, and built on surrogate endpoints, and the PEARL trial missed its primary endpoint. The 5 to 10 mg weekly schedule people use is not validated by any long-term outcome trial.
• Tirzepatide vs semaglutide: what the trials show (GLP-1; 8 min read). Tirzepatide and semaglutide are the two dominant GLP-1-class drugs in 2026. There is now a direct obesity head-to-head (SURMOUNT-5) and a diabetes head-to-head (SURPASS-2), and both went to tirzepatide on weight. It covers the pharmacology, the full STEP and SURMOUNT trial programs, the cardiovascular data (including the 2025 SURPASS-CVOT readout), the shared thyroid boxed warning, and the compounded-versus-labeled gap, then says what the comparison does and does not settle.

For research and educational purposes only. Not medical advice.